We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+7.6%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$696M
AUM Growth
+$65M
Cap. Flow
+$38.4M
Cap. Flow %
5.52%
Top 10 Hldgs %
28.66%
Holding
112
New
8
Increased
33
Reduced
36
Closed
4

Top Buys

Rank Stock Value
1
NVCR icon
NovoCure
NVCR
+$15.7M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$12M
3
EXEL icon
Exelixis
EXEL
+$8.89M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.34M
5
SNY icon
Sanofi
SNY
+$7.65M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$10.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.58M
3
SUPN icon
Supernus Pharmaceuticals
SUPN
+$7.12M
4
ESPR
Esperion Therapeutics
ESPR
+$6.62M
5
BIIB icon
Biogen
BIIB
+$5.16M

Sector Composition

Rank Sector Weight
1 Healthcare 92.59%
2 Financials 0.93%
3 Technology 0.13%
4 Energy 0.1%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
76
Ultragenyx Pharmaceutical
RARE
$2.55B
$2.21M 0.32%
+35,573
New +$2.14M
CMRX
77
DELISTED
Chimerix, Inc.
CMRX
$2.18M 0.31%
400,000
– –
TTPH
78
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.14M 0.31%
15,000
– –
BIVV
79
DELISTED
Bioverativ Inc. Common Stock
BIVV
$1.86M 0.27%
31,000
– –
PODD icon
80
Insulet
PODD
$9.66B
$1.8M 0.26%
35,000
– –
HALO icon
81
Halozyme
HALO
$10.2B
$1.54M 0.22%
120,000
-50,000
-29% -$668K
SUPN icon
82
Supernus Pharmaceuticals
SUPN
$2.72B
$1.29M 0.19%
30,000
-200,000
-87% -$7.12M
RAD
83
DELISTED
Rite Aid Corporation
RAD
$1.03M 0.15%
+17,500
New +$1.32M
ACAD icon
84
Acadia Pharmaceuticals
ACAD
$4.9B
$837K 0.12%
30,000
-60,000
-67% -$1.79M
ACHN
85
DELISTED
Achillion Pharmaceuticals
ACHN
$762K 0.11%
166,000
– –
STAA icon
86
STAAR Surgical
STAA
$1.15B
$755K 0.11%
69,950
+41,239
+144% +$403K
FWP
87
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$744K 0.11%
+5,226
New +$727K
RGLS
88
DELISTED
Regulus Therapeutics
RGLS
$585K 0.08%
4,947
– –
JPM icon
89
JPMorgan Chase
JPM
$947B
$442K 0.06%
4,837
– –
ATXS
90
DELISTED
Astria Therapeutics
ATXS
$441K 0.06%
5,179
– –
CNCE
91
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$420K 0.06%
30,099
– –
WFC icon
92
Wells Fargo
WFC
$265B
$405K 0.06%
7,305
– –
XOM icon
93
ExxonMobil
XOM
$642B
$389K 0.06%
4,823
– –
ADVM
94
DELISTED
Adverum Biotechnologies
ADVM
$385K 0.06%
15,401
– –
OCUL icon
95
Ocular Therapeutix
OCUL
$1.92B
$371K 0.05%
40,000
– –
ICPT
96
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$364K 0.05%
3,008
-26,992
-90% -$3.13M
OREX
97
DELISTED
Orexigen Therapeutics, Inc.
OREX
$348K 0.05%
120,000
– –
HAL icon
98
Halliburton
HAL
$27.1B
$330K 0.05%
7,718
– –
MSFT icon
99
Microsoft
MSFT
$3.71T
$330K 0.05%
4,793
– –
F icon
100
Ford
F
$55B
$318K 0.05%
28,404
+5,893
+26% +$65.8K
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
OC
Oarsman Capital Milwaukee, Wisconsin $806M AUM 19.96% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Rhenman & Partners Asset Management held 112 positions worth $696M, up 10% from $631M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management deployed $38.4M of net new capital in Q2 2017, opening 8 new positions and adding to 33 existing holdings. Its largest new stake was NovoCure: 1,216,314 shares worth $21M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Amgen, an estimated $10.6M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2017 buy was NovoCure: 1,216,314 shares worth $21M.
  • Rhenman & Partners Asset Management added most to Exelixis in Q2 2017, an estimated $8.89M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2017 reduction was Amgen, cutting an estimated $10.6M.
  • Rhenman & Partners Asset Management fully exited Viatris in Q2 2017, selling an estimated $3.51M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $696M portfolio in Q2 2017.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 4 in Q2 2017.
  • Rhenman & Partners Asset Management's portfolio value rose 10% quarter-over-quarter to $696M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2017, filed 11 Jul 2017.